SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (261)12/15/2002 12:15:11 PM
From: tuck  Read Replies (1) of 469
 
Here we go: 100mg, three times daily. Here's the leaflet from EMEA website (since OGS site is not cooperating today):

emea.eu.int

Sort of interesting that it is not based on body weight. Really wonder what dosage van der Spoel et. al. were giving those mice, and at what dosage the neurological effects show up. Anyone get the hard copy of PNAS?

Maybe I haven't been paying close enough attention, because I wasn't aware of this: the leaflet says that the side-effects -- including weight lose, flatulence, and neuropathy -- are usually transient, starting at the beginning of treatment and tapering off. Thank God for small blessings. Makes the possibilty of approval for contraception somewhat less remote. Anyone seen data on OGT - 923? I saw a vague reference to a better side effect profile. More hunting . . .

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News